Ishita Drugs & Industries Ltd has closed its trading window for designated persons starting October 1, 2026. The restriction remains in effect until 48 hours after the company declares its unaudited financial results for the quarter ended September 30, 2026.

This action is taken pursuant to the SEBI (Prohibition of Insider Trading) Regulations, 2015, and the company's internal Code of Conduct. These regulations mandate that insiders refrain from dealing in securities during periods when price-sensitive information is likely to be disclosed.

Regulatory Compliance and Timeline

The closure applies to all Designated Persons of the company as defined under the regulatory framework. The specific dates for the blackout period are outlined below:

The Managing Director, Jagdish Agrawal, signed the intimation submitted to BSE Limited on September 26, 2026. This filing ensures that all market participants are aware of the restrictions on insider trading during the sensitive period leading up to the earnings announcement.

Ishita Drugs & Industries Limited has entered into a loan agreement with HDFC Bank Limited for ₹11.75 crore to finance the upgradation of its manufacturing facility in Sanand, Gujarat.

The borrowing aligns with the company's plan to comply with the Revised Schedule M for pharmaceutical manufacturing. The approval was formalized during a board meeting on September 22, 2026, following a sanction letter from HDFC Bank dated September 17, 2026. The limits were previously sanctioned by shareholders at the 31st Annual General Meeting held on September 30, 2024, under Section 180(1)(c) of the Companies Act, 2013.

Breakdown of approved facilities

The financial instruments comprising the total borrowing are detailed below:

Purpose and security details

The primary purpose of the agreement is to raise funds for financing the upgradation project at the company's manufacturing facility located at Survey No. 179/1, Village Vasna Iyava, Taluka Sanand, District Ahmedabad. This upgrade is specifically aimed at meeting regulatory compliance standards under the Revised Schedule M.

HDFC Bank has secured a first charge on both immovable and movable assets of the company situated at the aforementioned Sanand location. The disclosure confirms that there are no special rights granted to the lender, such as director appointment rights or restrictions on capital structure changes. The transaction does not fall within related party transactions, and HDFC Bank holds no shareholding in the entity.

Meeting details and compliance

The board meeting commenced at 2:30 pm and concluded at 3:15 pm. Jagdish Agrawal, Managing Director, signed the intimation notice. The company is headquartered in Ahmedabad. The disclosure was made pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.